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What is the key message? 47 
• Faecal pH is a physiological parameter that has been correlated with fat 48 
absorption in children with cystic fibrosis 49 
What does it add to the existing literature? 50 
• Faecal pH, as a surrogate marker of intestinal pH, could explain why 51 
pancreatic enzyme replacement therapy is not effective for all the patients 52 
• Use of proton pump inhibitors is associated to higher values of faecal pH 53 
What is the impcat? 54 
• Faecal pH could be used as a biomarker to routinely monitor the efficacy of 55 
pancreatic enzyme replacement therapy in the clinical practice 56 
• Strategies to increasing intestinal pH in children with cystic fibrosis should be 57 
targeted in the clinical practice  58 
 4 
ABSTRACT 59 
Background: Despite treatment with pancreatic enzyme replacement therapy 60 
(PERT), patients with Cystic Fibrosis (CF) can still suffer from fat malabsorption.  A 61 
cause could be low intestinal pH disabling PERT. The aim was assessing 62 
association between faecal pH (as intestinal pH surrogate) and coefficient of fat 63 
absorption (CFA). Additionally, faecal free fatty acids (FFA) were quantified to 64 
determine the amount of digested but unabsorbed fat. 65 
Methods: In a 24h pilot study, CF patients followed a standardized diet with fixed 66 
PERT doses, corresponding to theoretical optimal doses (TOD) determined by an in 67 
vitro digestion model. Study variables were faecal pH, fat and FFA excretion, CFA 68 
and transit time. Linear mixed regression models were applied to explore 69 
associations. 70 
Results: in 43 patients, median (1st, 3rd quartile) faecal pH and CFA were 6.1 (5.8, 71 
6.4) and 90% (84,94) and they were positively associated (p<0.001). Inverse 72 
relationship was found between faecal pH and total fat excretion (p<0.01), and total 73 
FFA (p=0.048). Higher faecal pH was associated with longer intestinal transit time 74 
(p=0.049) and the use of proton pump inhibitors (p=0.009).  75 
Conclusions: Although the clinical significance of faecal pH is not fully defined, its 76 
usefulness as a surrogate biomarker for intestinal pH should be further explored. 77 
 78 
Word count: 3030  79 
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INTRODUCTION 80 
Around 85% of paediatric patients with Cystic Fibrosis (CF) suffer from 81 
pancreatic insufficiency. The obstruction of the pancreatic duct precludes the release 82 
of pancreatic enzymes into the intestine, resulting in nutrient maldigestion and 83 
malabsorption 1.  84 
Pancreatic Enzyme Replacement Therapy (PERT) consists in the exogenous 85 
administration of encapsulated pancreatic enzymes (amylase, protease and lipase) 86 
with every meal, and is the standard of care to treat pancreatic insufficiency, and 87 
thereby to help prevent malnutrition 1,2. While digestion of carbohydrates and protein 88 
is generally satisfactory, digestion of fat can be compromised despite of PERT 3,4. 89 
Pancreatic lipase requires an alkaline pH for optimal activity (it is inactive at pH lower 90 
than 5.5), which is altered in CF due to decreased secretion of sodium bicarbonate 91 
into the duodenum 4,5.  The complete process of fat digestion (fat hydrolysis or 92 
lipolysis) implies the breakdown of triglyceride molecules into free fatty acids (FFA) 6 93 
and their absorption in the intestine 7,8. If digestion is disturbed due to abnormally low 94 
pH and/or lack of pancreatic enzymes, triglycerides would neither be hydrolysed nor 95 
absorbed and would be excreted in the faeces as non-digested fat 6,9. On the other 96 
hand, it is possible that fat is hydrolysed into FFA, but not absorbed due to bile acid 97 
deficiency resulting in lack of micelle formation 10.  98 
In fact, previous research confirmed that small bowel pH in CF is positively 99 
associated with the efficacy of PERT. Lipid digestion was evaluated in several 100 
studies within MyCyFAPP Project 11; first, an in vitro study determined the theoretical 101 
optimal doses (TOD) of enzymes needed for maximum lipolysis from different food 102 
products, in the CF-specific intestinal environment 9. The TODs were next evaluated 103 
in an in vivo pilot study: all patients adhered to the same standard 24h diet and used 104 
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the same dose of PERT (the TOD), to identify patient specific factors that influence 105 
lipolysis 12. This resulted in a median CFA of 90% 12 suggesting that adjustment of 106 
PERT on TOD was accurate enough for adequate dietary fat digestion and 107 
absorption. However, a subgroup of the study population could not reach the 90% 108 
clinical target, and none of the studied patient characteristics so far could explain this 109 
result. Therefore, we hypothesized that a low small intestine pH could have caused 110 
insufficient PERT activity, leading to fat maldigestion and malabsorption, as 111 
previously reported in a small series of patients with CF 6. In addition, we 112 
hypothesised that assessing FFA excretion could be an indicator of the efficacy of 113 
the administrated PERT dose, as its presence in faeces would indicate digestion was 114 
effective, but further absorption was impaired.  115 
To test this hypothesis, the faecal samples collected in MyCyFAPP study 116 
were further assessed for pH and FFA, in addition to fat excretion quantification. 117 
Given the impossibility to assess intestinal pH in this series of patients, faecal pH 118 
was explored as a surrogate marker.  119 
Therefore, the objective of the present study was to further investigate the 120 
association between CFA and faecal pH. Secondarily we aimed to explore total 121 
faecal FFA concentration as an additional biological indicator of the efficacy of the fat 122 
digestion process in patients with controlled dietary fat and PERT intake.  123 
 124 
PATIENTS, MATERIALS, AND METHODS 125 
Subjects and study design 126 
 Study patients were regularly followed at 5 European CF Centres (Madrid, 127 
Valencia, Milan, Leuven and Rotterdam), with a confirmed CF diagnosis, pancreatic 128 
insufficiency, age between 2 and 18 years in stable gastrointestinal and respiratory 129 
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conditions since at least 2 weeks before signing the informed consent. Acute 130 
infections, use of antibiotics, severe cholestasis and changes in the usual treatment 131 
during the 2 weeks before enrolment were considered exclusion criteria. Details 132 
about inclusion and exclusion criteria, and the study design are explained in detail in 133 
a previous publication by our group 12. The Ethics Committees of all the participating 134 
centres approved the study protocol.  135 
 Patients were instructed to adhere to a standardised 24h test diet with 136 
corresponding fixed PERT doses (based on the TODs, obtained during the in vitro 137 
studies) 9. In this way, the influence of patient-specific characteristics on fat digestion 138 
could be evaluated. The diet consisted of five meals, starting with an afternoon 139 
snack (bread toasted bread with butter and jam) and dinner (ham and cheese 140 
sandwich) on the first day, and breakfast (milk with breakfast cereal), morning snack 141 
(yoghurt and orange juice) and lunch (pizza and dairy desert) on the second day. 142 
Portions could be adjusted according to age and individual preferences. PERT doses 143 
were strictly instructed per each meal, corresponding to the TOD. Encapsulated dyes 144 
(E-120, red carmine and E-132, indigo blue) were ingested at start and end of the 145 
24h fixed diet in order to identify the faeces specifically pertaining to the study period 146 
12. 147 
Clinical parameters obtained were age, gender, genotype, PPI use, transit 148 
time, total faecal fat (and the subsequent calculated coefficient of fat absorption), 149 
total faecal FFA and faecal pH. 150 
 151 
Faecal analyses 152 
 The faecal samples were frozen (-20 to -80 ºC) and shipped from all the 153 
participating centres to the central lab in Instituto de Investigación Sanitaria La Fe 154 
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(Valencia, Spain) for analysis. Since there is no well described or generally accepted 155 
standardised method for homogenisation of faecal samples in the literature 13-16, the 156 
homogenisation of samples was carried out carefully after thawing at room 157 
temperature. The samples that were not dyed were discarded before 158 
homogenisation. Faeces were mixed with 750 W stirrers (Braun MQ735) until 159 
complete homogenisation was obtained (approx. 5 minutes per sample, depending 160 
on the consistency and volume).  161 
Total faecal fat 162 
Total faecal fat (which does not differentiate between triglycerides and free 163 
fatty acids) was quantified on the homogenised faecal samples (10 g) with infrared 164 
spectroscopy, the gold standard to analyse fat in faeces 1. Random selected 165 
samples (n=10) were used to evaluate the developed homogenisation protocol.  166 
Coefficient of fat absorption (CFA) 167 
The CFA was calculated as the percentage of grams of fat excreted in the 168 
collected faeces relative to the grams of fat in the test diet 12-17. This parameter is 169 
considered equivalent to the % lipolysis extent used in the in vitro setting. Transit 170 
time was calculated as the time between the ingestion of the colour markers and the 171 
moment the first dyed-stool appeared. 172 
Free fatty acids in faeces 173 
 Aliquots from the homogenised faecal samples (5 g) were lyophilised and 174 
esterified. Then the FFA profile was characterised by gas chromatography-mass 175 
spectrometry (GC-MS) technique 18. 176 
Faecal pH measurement 177 
Aliquots from the homogenised samples (5 g) were thawed at room 178 
temperature and then mixed with 10 ml of deionized water and homogenized 1-2 min 179 
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using, firstly, a vortex and then using a horizontal shaker for 10 min (200 rpm). 180 
Faecal pH was measured by directly inserting the glass electrode of the Accumet 181 
AE150 pH Benchtop-Meter (Fisher Scientific) into the homogenized faeces. 182 
Measurements were taken twice per sample. In addition, in a random selection of 20 183 
samples, pH was measured at three moments over a period of 24 h and repeated 1 184 
month later to assess possible changes in the measurement over time. 185 
 186 
Statistical analysis 187 
A pilot study was conducted, provided that there was not an estimated effect 188 
or association to refer to given the lack of bibliography about the association 189 
between CFA and faecal pH. Therefore, an estimation of the statistical power was 190 
not required. Preparatory studies are designed to test the performance 191 
characteristics and capabilities of measures, procedures and operational strategies 192 
and or provide the means to evaluate aspects of novel approaches 19,20. 193 
Recommended sample sizes for pilot study range between 10-30 participants for 194 
pilot studies 21. 195 
A beta regression model was used to study the effect of the faecal pH on the 196 
CFA. Logarithmic transformation of faecal fat in stools and transit time was 197 
performed to approach a normal distribution with normalised extreme values. The 198 
association between faecal pH with the total amount of fat in stools (g) was studied 199 
by a univariate linear regression model, and the effect of the faecal pH on total FFA 200 
(mg/g faeces), and the effect of FFA on CFA, by means of a linear regression robust 201 
model). Finally, a linear regression multivariate robust model was established to 202 
study the association of age, transit time and use of PPI on faecal pH.  203 
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Analyses were carried out using the R software (version 3.5.1) and the 204 
libraries betareg (version 3.1-0), clickR (version 0.3.64) and MASS (version 7.3-49). 205 
A p value <0.05 was considered statistically significant. 206 
 207 
RESULTS 208 
Patients characteristics and descriptive results 209 
Forty-three children with CF were included. The study population 210 
characteristics were previously described by Calvo-Lerma et al. and are summarized 211 
in table 1 (2019) 12.  212 
 213 
Association of faecal pH with CFA, and free fatty acid excretion 214 
 As shown in Table 1, the median total amount of fat in faeces was 8.4 (4.8, 215 
12.3) g resulting in a median CFA of 90% with a small range between 1st and 3rd Q 216 
(84, 94%). The total amount of free fatty acids was 2.3 (1.6, 3.6) mg/g of faeces. The 217 
median pH of the samples was 6.08 (5.78, 6.38), with a minimum pH of 5.26 and a 218 
maximum of 6.85.  219 
Reproducibility of the faecal pH measurement was high, with a mean 220 
standard deviation of 0.02 when measuring the pH at three different points of the 221 
homogenized sample. Changes in the pH measurement along a 24 h period were 222 
not detected. Test results were highly reproducible (CV <15%) between two different 223 
aliquots of the same homogenised sample. 224 
 The faecal pH was significantly associated with the CFA (p<0.001, R2 = 0.42) 225 
(Figure 1A), with higher pH values relating to higher CFA. This result is confirmed 226 
by the significant inverse relationship between the pH and the total amount of fat in 227 
faeces (Figure 1B), as the diet was fixed (p<0.001, R2 = 0.38). This finding was also 228 
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reinforced by the inverse association between faecal pH and the total amount of 229 
FFA (Figure 1C) (p = 0.048, R2 = 0.35): the lower the pH the higher the total amount 230 
of fat and FFA in faeces.  231 
 When considering patients adhered to PPI therapy separately, median faecal 232 
pH values was 6.34 (6.09, 6.72), and in patients without following this therapy the 233 
value was found to be 5.91 (5.57, 6.31), the difference being statistically significant 234 
(p<0.01) (Figure 2).  235 
Fecal pH was positively and significantly associated with transit time (p = 236 
0.049 and with the use of PPI (p = 0.009) in a multivariable analysis (Table 2). In 237 
contrast, neither the age of the patient nor any of the other study variables showed 238 
any association with faecal pH values. 239 
In addition, the association between CFA and FFA excretion was studied 240 
(Figure 2). Low CFA being associated with high amount of faecal FFA (p<0.001) 241 
suggests that lipolysis is occurring, but the FFAs were not being absorbed. Low 242 
amounts of FFA in faeces were associated with higher values of CFA (p<0.001), 243 
suggesting that triglyceride molecules were properly hydrolysed, resulting in FFA 244 
release and absorption. In contrast, low absorption of fat was associated with high 245 
amount of excreted FFA.  246 
 247 
DISCUSSION 248 
 In this study we tried to further explore the mechanisms of fat absorption in 249 
CF. We have therefore characterised total fat and FFA excretion and pH in faecal 250 
samples of children with CF adhering to a standardised diet and using fixed doses of 251 
PERT, based on a CF specific in vitro digestion model. Both faecal pH and FFA were 252 
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used as an investigational tool. Faecal collection was very accurate being performed 253 
between colorimetric dyes, and this enabled also to measure transit time. 254 
First, we found that faecal pH was positively associated with CFA, and was 255 
inversely related with total FFA. In our previous study we concluded that when using 256 
the in vitro predicted optimal dose of enzymes (TOD), CFA was not associated with 257 
any of the assessed patients’ characteristics (genotype, nutritional status, lung 258 
function, age) with the only exception of transit time 12. We concluded that other 259 
patients’ characteristics could have had an impact on CFA, particularly intestinal pH 260 
12. Thus, the present findings on faecal pH, could explain why some patients did not 261 
reach the 90% target CFA, supporting the hypothesis of the present work: the 262 
association between faecal pH and CFA suggests that the TOD cannot achieve 263 
satisfactory levels of fat digestion in patients with a faecal pH lower than the pH 264 
range for lipase activity. Secondly, we found that faecal FFA is associated with CFA. 265 
Higher CFA was related to lower FFA excretion, suggesting that in patients 266 
with satisfactory fat digestion, the absorption of delivered FFA must have been 267 
efficient, as low amounts were present in faeces. Thus, this finding also suggests 268 
that when the in vitro predicted dose of PERT was prescribed, fat was not only well 269 
digested but also well absorbed. Conversely, some patients with low CFA tended to 270 
have high FFA excretion, pointing at possible further malabsorption problems. 271 
However, none of these patients characteristics could explain this finding.  272 
A previous study by our group has shown the strong influence of the intestinal 273 
pH on lipolysis under simulated in vitro gastrointestinal digestion 9,22,23. One of the 274 
few studies found in the literature showed that patients on tube feeding (n = 18) with 275 
low intestinal pH profiles were unable to reach satisfactory levels of fat digestion and 276 
absorption, despite high PERT doses 6. Compared to this study, our sample size 277 
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was larger (n = 43), patients were on a normal diet (rather than being on enteral 278 
nutrition), and faecal pH was measured as a surrogate of intestinal pH (given the 279 
impossibility to assess it because of ethical restrictions and need for invasive 280 
techniques). Robinson et al. (1990), in contrast, performed a direct measurement of 281 
the intestinal pH. Both studies, however have reached the same finding of the 282 
association between intestinal pH and fat absorption. Also, the proportion of patients 283 
with a very low intestinal pH (<5.8) was similar in both studies (around 20%).  284 
Complementarily, other digestion agents, such as bile salts concentration, have 285 
proved to exert a relevant role in fat digestion and absorption. Malabsorption of bile 286 
acids occur in patients with CF, and abnormal biliary secretion or intraluminal acidic 287 
precipitation of bile acids could contribute to steatorrhea (REF). In addition, the study 288 
of the impact of reduced bile salts concentration in the context of in vitro digestion 289 
study of several foods, has repeatedly been associated with decreased extents of 290 
lipolysis (REF).  291 
Possible determinants for faecal pH values were explored, finding that PPI 292 
use and longer transit time were associated with higher pH values. Studies 293 
evaluating the pH profile along the gastrointestinal tract in a healthy population by 294 
using the wireless motility capsule and radiotelemetry device support the main 295 
assumption that faecal pH may be considered as a surrogate for intestinal pH, as pH 296 
in the duodenum (lipid digestion) and rectum (before faecal deposition) were 297 
equivalent 10,24,25. In case of CF, concretely, pH along the first hour of small intestine 298 
digestion ranges between 5 and 7 24,26, in agreement with the pH range found in the 299 
faecal samples of our patients. Overall, the mean intestinal pH reported by Aburb et 300 
al. (2018) for healthy subjects was 6.2 and, in our cohort, median 6.02 was obtained. 301 
Despite this difference could appear to be small, a decrease of 0.2 in pH in terms of 302 
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lipase enzyme activity can imply a substantial reduction of fat digestion (REF). In 303 
addition, this difference in pH becomes higher when only considering those patients 304 
not following the PPI therapy, which would be reflected in lower fat digestion.    305 
Our findings also showed that patients taking PPI had higher faecal pH. 306 
Treatment with PPI reduces gastric acid secretion and leads to less acidic stomach 307 
environment during digestion 27. As a consequence, the gastric contents enter the 308 
duodenum with a more alkaline pH than the usual, thus modifying the intestinal 309 
conditions towards a normal environment, despite the limited pancreatic bicarbonate 310 
secretion in patients with CF 10,18.   311 
The strengths of this study include the accuracy of faecal collection using 312 
colorimetric markers. The samples are of unique value since for the first time to our 313 
knowledge, they represent the product of the digestion and absorption of the same 314 
diet and the same PERT doses followed by a cohort of 43 patients with CF. It was 315 
therefore possible to assess differences in CFA only in terms of individual patients’ 316 
characteristics, avoiding confounding factors related to the diet or the variability in 317 
PERT. Another strength relies on the GC-MS technique used, the most accurate and 318 
state of the art method to quantify free fatty acids 28. 319 
On the other hand, the main limitation of the present study is the assumption 320 
that faecal pH reflects the pH of the small intestine. In the colon, several reactions 321 
occur, including fermentation of unabsorbed or undigested nutrients (carbohydrates, 322 
protein) by some specific bacteria conforming the microbiota. This results in the 323 
production of short chain fatty acids, which may reduce the luminal pH. However, 324 
even if the study subjects could have different microbiota profiles, the production of 325 
short chain fatty acids is highly dependent on the pattern of food intake 29, and all of 326 
our patients had the same standardised meals. Thus, our positive findings support 327 
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the inclusion of microbiota assessment in future series. Another factor possibly 328 
modifying the pH in the colon is related to carbohydrates malabsorption 30, which 329 
however was unlikely to be present in our patients since normally it is associated to 330 
liquid stools 31 (present in only one of our patients 12). In light of the significant 331 
association between faecal pH, total faecal fat and free fatty acids and CFA, along 332 
with the comparable range of pH as in previous series, we suggest this indirect 333 
measurement could reflect at least in the intestinal conditions. These findings 334 
support conducting a future study to validate the relationship between intestinal pH 335 
and faecal pH in these population, so faecal pH could be considered as a non-336 
invasive biomarker of the intestinal pH and provide insight on the mechanism of 337 
malabsorption.  338 
The strong association and moderate correlation between faecal pH and CFA 339 
reinforces the previous data obtained by our research group, indicating that 340 
strategies aimed at increasing intestinal pH may result in better fat absorption. Thus, 341 
our results support the use of PPI therapy in addition to PERT in patients with low 342 
CFA but already taking high doses of PERT, as previously concluded by Robinson et 343 
al. (1990) 6. However, the clinical value of using faecal pH to guide management 344 
requires further evaluation. It should be always kept in mind that long-term PPI 345 
treatment may lead to complications by suppressing the natural barrier of the gastric 346 
acid against pathogenic bacteria 32. It has been associated with an increase number 347 
of pulmonary exacerbation and hospitalisation 33. 348 
Another clinical application, although with possible limitations, would be 349 
measuring pH in faeces as a complementary qualitative method to indirectly assess 350 
fat digestion and absorption. It is a simple, non-invasive and fast technique that only 351 
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requires a pH-metre, a common and not expensive equipment. This technique could 352 
possibly complement the 24h faeces collection.  353 
In conclusion, faecal pH is suggested as a possible factor explaining 354 
differences found in the CFA in a cohort of patients with CF that followed the same 355 
diet and had the same doses of PERT according to an in vitro evidence-based 356 
method. Strategies to increase the intestinal pH in CF are encouraged in order to 357 
enhance lipid digestion, being aware of the potential side effects. In addition, the use 358 
faecal pH as surrogate for fat malabsorption could be a fast and easy technique, 359 
which with pertinent additional validation, could be used in the clinical practice.  360 
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FIGURE LEGENDS 458 
 459 
Figure 1. Faecal pH values are (A) positively associated with the coefficient of fat 460 
absorption (CFA); (B) negatively associated with the faecal fat excreted; and (C) 461 
negatively associated with the free fatty acid (FFA) excretion. 95% CI, confidence 462 
interval of the estimated effect. 463 
 464 
Figure 2. Patients adhered to therapy with proton pump inhibitors (PPI) (n=14) 465 
obtained significantly higher median faecal pH than those not following this therapy 466 
(n=28). 467 
 468 
Figure 2. Figure 3. Free fatty acid (FFA) excretion is negatively associated with the 469 
coefficient of fat absorption (CFA). 95% CI, confidence interval of the estimated 470 
effect. 471 
